Search research articles
Contact Us
Filters
Showing results (21-30 of 29) with videos related to
Page
of 3
Sort By:
You have reached the last page of results.
This site can display upto 29 results.
Bioorganic & Medicinal Chemistry Letters
|
November 28, 2006
1,3-Disubstituted-imidazo[1,5-a]pyrazines as insulin-like growth-factor-I receptor (IGF-IR) inhibitors
Mark J Mulvihill, Qun-Sheng Ji, Doug Werner, et al.
Bioorganic & Medicinal Chemistry
|
November 7, 2007
Novel 2-phenylquinolin-7-yl-derived imidazo[1,5-a]pyrazines as potent insulin-like growth factor-I receptor (IGF-IR) inhibitors
Mark J Mulvihill, Qun-Sheng Ji, Heather R Coate, et al.
ACS Medicinal Chemistry Letters
|
June 6, 2014
Discovery of an Orally Efficacious Imidazo[5,1-f][1,2,4]triazine Dual Inhibitor of IGF-1R and IR
Meizhong Jin, Prafulla C Gokhale, Andy Cooke, et al.
Bioorganic & Medicinal Chemistry Letters
|
March 1, 2011
Imidazo[1,5-a]pyrazines: orally efficacious inhibitors of mTORC1 and mTORC2
Andrew P Crew, Shripad V Bhagwat, Hanqing Dong, et al.
Bioorganic & Medicinal Chemistry Letters
|
July 16, 2013
Discovery and optimization of 7-aminofuro[2,3-c]pyridine inhibitors of TAK1
Keith R Hornberger, Dan M Berger, Andrew P Crew, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
May 31, 2024
Oral Estrogen Receptor PROTAC Vepdegestrant (ARV-471) Is Highly Efficacious as Monotherapy and in Combination with CDK4/6 or PI3K/mTOR Pathway Inhibitors in Preclinical ER+ Breast Cancer Models
Sheryl M Gough, John J Flanagan, Jessica Teh, et al.
Bioorganic & Medicinal Chemistry Letters
|
June 19, 2013
Novel 6-aminofuro[3,2-c]pyridines as potent, orally efficacious inhibitors of cMET and RON kinases
Arno G Steinig, An-Hu Li, Jing Wang, et al.
ACS Medicinal Chemistry Letters
|
April 15, 2026
DNA-Encoded Library (DEL) Selection Identifies a Distinct DDB1 Ligand Binding Site
Shiva Krishna Reddy Guduru, John P Caldwell, Katherine M Digianantonio, et al.
Journal of Medicinal Chemistry
|
May 21, 2025
Correction to "PROTACs Targeting BRM (SMARCA2) Afford Selective <i>In Vivo</i> Degradation over BRG1 (SMARCA4) and Are Active in BRG1 Mutant Xenograft Tumor Models"
Michael Berlin, Jennifer Cantley, Mark Bookbinder, et al.
Page
of 3
Search research articles
Search
Showing results (21-30 of 29) with videos related to
Sort By:
Page
of 3
You have reached the last page of results.
This site can display upto 29 results.
Bioorganic & Medicinal Chemistry Letters
|
November 28, 2006
1,3-Disubstituted-imidazo[1,5-a]pyrazines as insulin-like growth-factor-I receptor (IGF-IR) inhibitors
Mark J Mulvihill, Qun-Sheng Ji, Doug Werner, et al.
Bioorganic & Medicinal Chemistry
|
November 7, 2007
Novel 2-phenylquinolin-7-yl-derived imidazo[1,5-a]pyrazines as potent insulin-like growth factor-I receptor (IGF-IR) inhibitors
Mark J Mulvihill, Qun-Sheng Ji, Heather R Coate, et al.
ACS Medicinal Chemistry Letters
|
June 6, 2014
Discovery of an Orally Efficacious Imidazo[5,1-f][1,2,4]triazine Dual Inhibitor of IGF-1R and IR
Meizhong Jin, Prafulla C Gokhale, Andy Cooke, et al.
Bioorganic & Medicinal Chemistry Letters
|
March 1, 2011
Imidazo[1,5-a]pyrazines: orally efficacious inhibitors of mTORC1 and mTORC2
Andrew P Crew, Shripad V Bhagwat, Hanqing Dong, et al.
Bioorganic & Medicinal Chemistry Letters
|
July 16, 2013
Discovery and optimization of 7-aminofuro[2,3-c]pyridine inhibitors of TAK1
Keith R Hornberger, Dan M Berger, Andrew P Crew, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
May 31, 2024
Oral Estrogen Receptor PROTAC Vepdegestrant (ARV-471) Is Highly Efficacious as Monotherapy and in Combination with CDK4/6 or PI3K/mTOR Pathway Inhibitors in Preclinical ER+ Breast Cancer Models
Sheryl M Gough, John J Flanagan, Jessica Teh, et al.
Bioorganic & Medicinal Chemistry Letters
|
June 19, 2013
Novel 6-aminofuro[3,2-c]pyridines as potent, orally efficacious inhibitors of cMET and RON kinases
Arno G Steinig, An-Hu Li, Jing Wang, et al.
ACS Medicinal Chemistry Letters
|
April 15, 2026
DNA-Encoded Library (DEL) Selection Identifies a Distinct DDB1 Ligand Binding Site
Shiva Krishna Reddy Guduru, John P Caldwell, Katherine M Digianantonio, et al.
Journal of Medicinal Chemistry
|
May 21, 2025
Correction to "PROTACs Targeting BRM (SMARCA2) Afford Selective <i>In Vivo</i> Degradation over BRG1 (SMARCA4) and Are Active in BRG1 Mutant Xenograft Tumor Models"
Michael Berlin, Jennifer Cantley, Mark Bookbinder, et al.
Page
of 3